View
37
Download
0
Category
Tags:
Preview:
DESCRIPTION
Social Innovation, the Public Good and the Invention-Innovation. David Castle Canada Research Chair in Science and Society Department of Philosophy University of Ottawa dcastle@uottawa.ca. We All Know What the Problem Is. - PowerPoint PPT Presentation
Citation preview
Social Innovation, the Public Good and the Invention-
Innovation
David CastleCanada Research Chair in Science and Society
Department of PhilosophyUniversity of Ottawadcastle@uottawa.ca
2003 Canadian business expenditures on R&D represented only 1.0% of GDP
U.S.’s 1.8% or the OECD average of 1.5%.
2005, the World Economic Forum ranked Canadian businesses 27th in the world in terms of their propensity to compete based on unique products and processes
2006, the Expert Panel on Commercialization (commissioned by the Prime Minister’s Advisory Council on Science and Technology) called for a Commercialization Partnership Board to address the invention-innovation
We All Know What the Problem Is
Post-Secondary Education Funding
CAUT - Almanac of Post-Secondary Education 2007
S&T Framework states Canada is the top-ranked publisher of peer-reviewed scientific papers based on publicly-funded research, but adds / captures little value
The Conference Board of Canada reports that private sector investment in training, learning and development in Canada is stagnant, and is slipping behind many of our international competitors .
The Council of Canadian Academies finds that fields with high growth potential are not associated with correspondingly consistent science and technology infrastructure, particularly in the regulatory domain that would generate confidence in health and safety, intellectual property protection, and environment and business framework regulation.
We All Know What the Problem Is
Vannevar Bush – Linear Model
Federal Investment
Social Benefit
Innovation Gap
S&T Framework
EntrepreneurialKnowledge
People
PPPsFirmsVC
Change Agents
Innovation Gap
PPPsFirmsVC
Change Agents
S&T Framework
EntrepreneurialKnowledge
People
TransferTranslation
Biotechnology IP
Riskmanagement
Knowledgemanagement
Sovereignty
Edu
catio
n/tr
aini
ng/d
egre
e
RevenuesBusiness capabilities, licensing
Media activiy
Revenues, public opinion awarness
Mul
tilate
ral t
rade
IP a
gre
ement
s
IP box
Integrity ofliving things
Distributivejustice
Economicefficiency
Innovation, technology transfer org, early $, basic $
Licensing, formal diff of knowledge, education/training/degree
Exclusionary value, award of patent
Sta
bilit
y of p
olit
ical i
nfra
stru
ctur
e
Scientific infra, innovation
Exclusionary value
Quality of risk analysis, media activity
Stability of political infrastructure
Weal
th
Scope reg diversity
International human rights
Inno
vatio
n
Patent eligible invention
Sal
es,
rev
enues
, wea
lth, f
inv
othe
r, f
inv
TS
Innov
atio
n
Sta
bili
ty o
f po
litic
al in
frast
ruct
ure
Sal
es,
rev
enues
, wea
lth d
istr
ibut
ion,
wea
lth
Non
tarif
f ba
rrie
r to
trade
Stability of political infra
Patent value, exclusionary value, value IPSales, revenue, public op awareness
Innovation, technology transfer org
Value of IP, exclusioanry value
Innovationmanagement
Biotechnology IP
Biotechnology IP
Biotechnology IP - PDV
Biotechnology IP - PDV
Biotechnology IP - PDV
Biotechnology IP - PDV
ProducedPDV
Mortality rate due tochronic infection
Mortality rate due toacute infection
Birth rateInfant population
Infant mortality rate+
Non-infant population
Mortality rate
+
-
B1
++
-B2 R1
+
Infected population
Acute cases
Chronic cases
Recovey rate afteracute infection
Virus carriers
+
+
+
+-
-
-
+
-
+ -
+-B3
B4
B5
B6 B7
B8
Market potential
B19
Adopters
Sales of imitativevaccines
+
+
-
+
-
+
+
-
R2
PDV stock
Production
Desired productionadjustment
+
-B9
Mechanical process
+
mechanical loss
+
-
B11
Concentration wash
Concentration loss
+
-
B13Formulation
Formulation loss
+
-
B15
++
+
-B18
Sales of vaccines
+
Sales of innovativevaccine
+
+
B14
-
B16
+-
-B10
- B12
-
B17
B20PDV cost per dose
Desired costadjustment
+ -B21
Total cost ofvaccination
+
+
+
Total PDV cost
+
R3
+
Biotechnology IP - PDV
0
50 000
100 000
150 000
200 000
250 000
2010
2013
2016
2019
2022
2025
2028
2031
2034
2037
2040
2043
2046
2049
Year
Nu
mb
er o
f ch
ild
ren
statu quo hyp 1 hyp 2 hyp 3
Central to the debate is the question of whether managed innovation within a federal system of devolved governance create appropriate enabling and sustaining social conditions for science and technology to flourish in Canada, and improve the well-being and wealth of Canadians.
Central Challenge
1. Systematic review of the governance of innovation which provides improved measures of the social-scientific impact of public and private investment in science and technology
2. Study of boundary-crossing science and technology where traditional categories of science and technology no longer apply, thus destabilizing the regulatory environment and public understanding of science and technology
Five Challenges
3. Development of a proactive technology assessment that combines ethical and scientific elements in the evaluation of a technology’s complete life-cycle
4. Extension of Canadian science and technology’s into the international context to address the imbalance in global health equity and food security and reestablish Canada’s preeminence in the development agenda
Five Challenges
5. Evaluation of environmental context of science and technology innovation to understand the impact on the social environment, health systems, and the natural environment
Five Challenges
Convergence in Biotechnology
1. Complexity obstacle
2. Regulatory culture obstacle
3. Reactive mode obstacle
4. Myth of sound science obstacle
5. Domestic focus obstacle
Innovation in Governance
• New methods – for evaluating the social return on science and technology investments, and assessing technological innovation as it arises in its social context
• New metrics – that ground new methods and models empirically in measures that better capture the social impact of innovation
• New models – to analyze and evaluate domestic science and technology governance, and to strengthen Canada’s position through international comparison
Social Innovation – NOW!
Acknowledgements
Recommended